Background: Post-transplant lymphoproliferative disorders (PTLD) are a complication of chronic immunosuppressive therapy in solid organ transplantation with a high mortality rate . Alternative treatments such as rapamycin have been explored. Methods: A detailed retrospective analysis was performed according to data collected from 13 patients with PTLD.
INTRODUCTION
Immunosuppressive therapy in kidney transplant recipients have successfully reduced the risk of rejection after kidney transplantation, however, malignancy and post-transplant lymphoproliferative disorder (PTLD) are common complications of immunosuppressive therapy [1] [2] [3] [4] [5] . The overall reported incidence of PTLD varies from approximately 1% in kidney transplant recipients to 33% in intestinal or multiorgan transplant 2 .
Immune status for Epstein-Barr virus (EBV) infection , the type and cumulative effect of immunosuppressive regimens are the major risk factors associated with PTLD 6 . In PTLD patients , immunosuppressive drugs inhibit the function of T cells and EBV-induced B-cell proliferation of lymphocytes 2 . The majority of PTLD histology is diffuse large B cell lymphoma 2, 3 . Therefore, reduction or withdrawal of immunosuppression recommended as first-line therapy for PTLD. Other modalities of treatment such as rituximab, chemotherapy or radiation therapy and antiviral agents can be considered if necessary 2, 6, 7 . However, the optimal treatment strategy still remains to be determined have confirmed that the calcineurin inhibitors (CNIs) increase the risk of EBV-related disease, whereas mammalian target of rapamycin( mTOR ) inhibitors have a potent anti-proliferative effect to inhibit the growth of B cells infected by EBV, prevention and treatment of PTLD without induced graft rejection [8] [9] [10] .Alternative treatment options such as therapy with mTOR inhibitors have been tried. There has been in vitro evidence that rapamycin, a new macrolide immunosuppressant drug, may reduce incidence of malignancy and inhibiting progression of PTLD without inducing rejection 4, 8, 11, 12 . Therefore, this therapeutic strategy can induce lytic EBV infection in the tumor cells via cell cycle arrest, induction of apoptosis and inhibition of interleukin-10 secretion 8 .
This report documents the result of rapamycin therapy in 13 patients with PTLD after kidney transplantation. At the time of PTLD diagnosis, all of the patients were treated with reduction in mycophenolate mofetil or azathioprine, discontinuation of cyclosporine or tacrolimus and administration of rapamycin 2 mg/day. If the patient did not respond during a period of 4 weeks, then other modalities of treatment were initiated. Rapamycin was given at a dosage of 2 mg/ day and has been continued with the same dose. Only one patient received rapamycin 3 mg/day at the time of PTLD diagnosis. If the patient is a suitable candidate for chemotherapy, rapamycin dosage is decreased to 1mg/day. A complete response (CR) was defined as the disappearance of all clinical disease evidence for at least 4 weeks. A partial response (PR) was defined as greater than 50% decrease in the bidimensional measurement of all disease sites and the absence of any new lesions. Progressive disease (PD) was defined as an increase of more than 25% in the size of lesion or the appearance of any new lesions. Time to failure was the interval from the initiation of therapy to progressive disease and disease relapse or death. Graft survival was defined as the time from PTLD diagnosis to death or dialysis. Overall survival was computed from the date of PTLD diagnosis to the date of death or last visit 3, 13 .
PATIENTS AND METHODS

Statistical Analysis:
Data were analyzed using Statistical Package for the Social Sciences (SPSS) version 16.0. Survival curves generated via the Kaplan-Meier method. For variables, the median or most frequent category was used.
RESULTS
Among 590 kidney transplant recipients, 13 patients with PTLD diagnosis enrolled in this study. The overall mean age at PTLD diagnosis was 42.15 (range: 25-58) and 69.2% of the patients were male. Demographic features of 13 patients, etiologies of renal disease and immunosuppression protocols are summarized in Table 1 . The clinical presentation of PTLD was highly variable. The median time from the first sign/symptom to the PTLD diagnosis was 2 months (range: 1-19 mos). Tissue biopsy performed to determine PTLD histology. At the time of PTLD diagnosis, creatinine levels ranged from 0.9 to 2.2 mg/dl and the mean Glomerular Filtration Rate(GFR) was 61.7 ml/min per 1.73 m2 (range: 33 -94.44 ml/min). 
Response to Rapamycin Alone Reduced immunosuppression in combination with
rapamycin was effective in induction of remission in 4 patients ( Table 4 ). All of the 4 patients presented with extranodal disease. Histological examination and immunophenotyping showed large B-cell lymphomas in these patients. One patient had involvement of the grafted organ and two were stage 4. According to age adjusted IPIindex, two patients were in low risk and 2 patient was in low intermediate risk group. These patients had an Eastern Cooperative Oncology Group Performance Score (PS) of 0 to 1. Complete remission was achieved after median time of 12 weeks. Repeated ultra sound and CT scans showed gradual regression of PTLD and resolution of lymphadenopathies in all of 4 patients. Median disease free survival was 37.5 months. Rapamycin therapy was effective therapy in maintaining graft survival in 75% of these four patients. Creatinine level ranged increased from 1-2.2 mg/dl to 1.3-2.4 mg/dl at the last visit, the mean GFR however did not change during followup, and was 48.5 ml/min. Only one patient of these four lost her graft function and returned to hemodialysis three months after start of rapamycin therapy.
Eight (61.5%) patients received a second treatment modality, which included rituximab in three patients, chemotherapy in three patients, rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) in two patients. Six (46.15%) patients achieved CR with rituximab or chemotherapy administration. Two patients died, one patient died due to Mycobacterium tuberculosis infection 1 month after have achieved CR, without any evidence of PTLD in autopsy and other died because of sepsis during R-CHOP therapy. One patient was treated with R-CHOP as a third treatment modality and expired because of PTLD progression 27 months after PTLD diagnosis.
In this study, 10 (76.9%) patients were considered to have CR. renal graft function remained stable in 11 (84.6%) patients from diagnosis through follow-up. At the last visit or time of death, creatinine levels ranged from 1 to 8. directly inhibits the growth of EBV + B cell lymphomas at doses that are therapeutically effective for prevention of graft rejection 8, 10 . Rapamycin has been utilized in the therapy of small samples of kidney transplant recipients with PTLD and have achieved a CR with low dose of this agent 16, 17. In a series reported by Julio Pascual 18 , 19 renal transplant recipients who developed PTLD were converted to PSIs (sirolimus n=16, everolimus=3). Calcineurin inhibitors (CNIs) were withdrawn in 18 patients and minimized in one patient. In this study, Rituximab therapy was used in 6 patients and chemotherapy with CHOP was also administered to 6 patients. Complete remission was observed in 15 patients who were maintained between 6 and 156 months. Graft function was observed in 10 patients, proteinuria reported in 3 cases and chronic allograft nephropathy reported in 2 cases. We present the results of rapamycin implementation in the management of 13 PTLD cases which occurred among 590 kidney transplant recipients at our center between 1990 and 2013. In this series, the response rate to rapamycin alone was 30.8%. In all of 4 patients who achieved a CR with rapamycin alone, pathology of tumor was DLBCL. Overall, 4 patients are still alive without infectious complications. Eight patients required treatment with second modality treatment and 2 patients died of infection. This result suggests that rituximab or R-CHOP therapy may increase the risk of infection in patients with PTLD. Only 2 of 13 patients experienced acute rejection at 3 and 12 months after the PTLD diagnosis, respectively. In total, 10 patients (76.9%) achieved a complete remission and 9 patients are alive. No patient experienced recurrence of PTLD. The mean overall survival period was 23.38 months. These data strongly suggest that rapamycin is a safe drug to administer in the treatment of patients with PTLD. Despite the retrospective focus and limited number of patients, this study provides promising results regarding the effectiveness of stopping CNIs and switching to rapamycin for patients with PTLD, however, it is not clear whether PTLD regression due to reduced immunosuppression or the potent anti-proliferative effect of rapamycin causes it or both.
